706
Participants
Start Date
June 21, 2016
Primary Completion Date
January 8, 2018
Study Completion Date
August 16, 2019
pembrolizumab + epacadostat
"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
pembrolizumab + placebo
"* Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~* Placebo will be administered orally daily starting at Day 1 (Week 1)"
Birmingham
Scottsdale
Little Rock
Los Angeles
San Francisco
Santa Barbara
Santa Monica
Aurora
Denver
Washington D.C.
Fort Lauderdale
Jacksonville
Ocala
West Palm Beach
Chicago
Peoria
Iowa City
Kansas City
Lutherville
Boston
Ann Arbor
Fridley
Billings
Omaha
Las Vegas
Rochester
Charlotte
Philadelphia
Nashville
Austin
Dallas
Salt Lake City
Fairfax
Spokane
Camperdown
Westmead
Wollstonecraft
Cairns
Greenslopes
Kurralta Park
Melbourne
Brussels
Ghent
North Vancouver
Ottawa
Toronto
Montreal
Santiago
Viña del Mar
Aarhus
Herlev
Odense C
Bordeaux
Lille
Marseille
Paris
Pierre-Bénite
Reims
Rennes
Toulouse
Villejuif
Buxtehude
Essen
Hanover
Kiel
Tübingen
Cork
Dublin
Galway
Ramat Gan
Bergamo
Genova
Milan
Napoli
Padua
Siena
Susono
Asahikawa
Chūō
Fukuoka
Kagoshima
Kumamoto
Kurume
Kyoto
Matsumoto
Nagoya
Niigata
Okayama
Osaka
Sapporo
Sendai
Tokyo
Tsukuba
Chihuahua City
Distrito Federal
Mexico City
Monterrey
Amsterdam
Nijmegen
Dunedin
Tauranga
Warsaw
Istra
Moscow
Saint Petersburg
Johannesburg
Sandton
Groenkloof
Cape Town
Kraaifontein
Seoul
Donostia / San Sebastian
A Coruña
Barcelona
Donostia / San Sebastian
Madrid
Pamplona
Seville
Valencia
Gothenburg
Lund
Stockholm
Uppsala
Zurich
Geneva
Lausanne
Edinburgh
London
Manchester
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Incyte Corporation
INDUSTRY